Background: Recruited myeloid cells are known to promote cancer initiation, ma-
| INTRODUCTION
Prostate cancer (PCa) is the most common cancer affecting men in the USA. 1 It is the third leading cause of cancer death for men in America and remains an important public health concern. As PCa progresses, it can evolve into metastatic castration-resistant PCa (mCRPC), a more lethal form marked by resistance to androgen deprivation therapy (ADT). The potential for immunotherapy directed against PCa is illustrated by sipuleucel-T (Provenge; the first modern immunotherapy approved for mCRPC), where Kantoff et al 2 showed a 22% reduction in death and minimal toxicity associated with its use. Accordingly, approval of sipuleucel-T remains an important milestone for the field of PCa. There was, however, little benefit observed in the regression of disease as assessed by serum prostate-specific antigen (PSA) or radiographs. These findings have left the field with many questions, but they have also clearly demonstrated that there is a potential role for immunotherapy in PCa. Approved modern immunotherapies, such as immune checkpoint inhibitors, have made their indelible mark on other solid-tumor cancers such as melanoma, lung cancer, and kidney cancer. Deeper investigation into the role of the human immune system in PCa is vital in order to harness this kind of immune potential directed at future PCa therapies.
Monocytes are an essential component of the circulating immune system; these cells are dynamic and respond to foreign information in the bloodstream by producing growth factors and cytokines. Monocytes comprise most of the infiltrating cells associated with solid tumors. 3, 4 Their recruitment and activation at tumor sites are largely regulated by tumor-derived signals including chemokines, cytokines, and other endogenous signals. 3 Following their recruitment into tumor tissues, monocytes can differentiate into tumorassociated macrophages (TAMs), a diverse population in both phenotype and function. As key components of the PCa tumor microenvironment, macrophages have been shown to exert a protumorigenic effect by facilitating tumor cell migration and invasion. 5 Our current knowledge, however, remains very limited regarding a plausible link between monocytes, macrophages, and PCa progression. Consequently, a more comprehensive understanding of the cellular interactions that contribute to PCa progression is necessary to support the development of effective immunotherapeutic strategies.
In the present study, we tested the hypothesis that circulating monocytes from advanced PCa patients directly influence the tumor microenvironment in distant organs such as the liver, lung, and bones and have a tumor-promoting phenotype. We found that monocytes from advanced PCa/ mCRPC (PCa-M) secreted significantly higher levels of IL-1β and chitinase-3-like 1 (CHI3L1) compared with monocytes from those with stable disease (PCa-N) which narrowed our focus to these two prospective proteins. Previous research has described an IL1-IL1R-dependent mechanism as being essential in shaping the tumor-promoting phenotype of monocytes and macrophages. 6 Additionally, macrophagederived IL-1β has been shown to influence the growth and regulation of androgen receptor (AR) and PSA levels in androgen-responsive prostatic epithelial cells (LNCaP). 7 The expression of CHI3L1 has been associated with a poor prognosis in PCa. Jeet et al 8 reported that some PCa cell lines synthesize CHI3L1, a chitinase-like protein, and this expression has been implicated in driving both migration and invasion of these cancer cells. Herein, our results suggest that monocyte-produced IL-1β is not responsible for the protumor phenotype of monocytes from PCa patients. However, we demonstrate that CHI3L1 plays an IL-13Rα2-dependent role in the invasiveness and motility of PCa cell lines in culture. Collectively, these findings are the first to demonstrate a critical role for circulating monocytes in the progression of PCa.
| METHODS

| Patients and samples
Blood specimens were collected and studied under CedarsSinai Medical Center Institutional Review Board approved protocols. Patient samples were classified into two categories: nonmetastatic (PCa-N) and metastatic (PCa-M). Healthy controls (HC) were classified as having no known history of cancer. The provided Table S1 indicates clinical characteristics of each patient sample used in this study.
receptor significantly reduced invasiveness of these cells in the presence of CM from PCa-M patients. Conclusions: Thus, we show that circulating monocytes from metastatic PCa patients exert a tumor-promoting role via the secretion of CHI3L1, and CHI3L1 demands further exploration as a possible therapeutic target in advanced PCa. were grown to confluence in matrigel-coated 96 wells plates (IncuCyte, Ann Arbor, MI, USA). After overnight fasting (0.1% BSA T-medium), a scratch was made using a 96-pin WoundMaker (IncuCyte, Ann Arbor, MI, USA) and monocyte-CM (50% v/v) from PCa-N, PCa-M, or HC or increasing concentrations of rhIL1β (0.2, 2, 20, and 100 ng/ mL) was added. Cells were automatically imaged every hour. The data were analyzed using an integrated relative wound density protocol as previously described and recommended by the manufacturer (IncuCyte, Ann Arbor, MI, USA). Fetal bovine serum (FBS; 10%) and rhHGF (50 ng/ mL) were utilized as positive controls for cell migration in ARCaP M and PC3 cells, 9 respectively. 
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| Cells and culture conditions
ARCaP M and C4-2 cells used for this study were provided by Dr. Leland Chung. PC3 cells were provided by Dr. Carrie Rinker-Schaeffer. LNCaP and 22Rv1 cells were purchased from ATCC. ARCaP M cells were cultured in T-medium (GibcoBRL, Grand Island, NY, USA) supplemented with 5% heat-inactivated FBS (Omega Scientific, Inc, Tarzana, CA, USA). PC3, C4-2, and 22Rv1 were cultured in RPMI 1640 with 10% FBS. LNCaP cells were cultured in RPMI 1640 with 10% FBS supplemented with 4.5 g/L glucose. Each had 50 IU/mL penicillin and 50 μg/mL streptomycin (GibcoBRL) and was maintained in 5% CO 2 at 37°C. All cells were negative for mycoplasma contamination (MycoAlert Mycoplasma Detection Kit, Lonza, Walkersville, MD, USA). Cell line authentications were verified via short tandem repeat analysis using a DNA collection kit (DDC Medical, Fairfield, OH, USA).
| MTT assay
In vitro cell proliferation was assessed using MTT assay as indicated by the manufacturer (ThermoFisher, Waltham, MA, USA) at day 6 of culture.
| Cytokine and chemokine array
Protein array (Proteome Profiler™ Human XL Cytokine Array Kit, R&D, Minneapolis, MN, USA) surveyed 102 proteins in monocyte-CM (50%v/v) of PCa-N, PCa-M, and HC according to manufacturer's instructions. The membrane was exposed to X-ray film for 300 seconds, and profiles of mean spot pixel density were measured using Western Vision Software specific for R&D array analysis.
| ELISA assay for chitinase-3-like 1 and
IL-1β
Proteins were assessed in cell-free monocyte supernatants (CM) using chitinase-3-like 1 Quantikine ELISA and IL-1β/ IL1-F2 Duo Set ELISA (R&D Systems) according to manufacturer's instructions. 
| Quantitative PCR
| Statistical analysis
Statistical significance was calculated by Student's t test when comparing two groups or by one-way ANOVA when comparing three or more groups. A P-value of ≤0.05 was considered statistically significant.
| RESULTS
| Monocyte-derived conditioned media from metastatic PCa/mCRPC patients promote PCa cell invasion and migration
Monocytes from PCa-M and PCa-N were analyzed for markers that designate classical "inflammatory" and nonclassical "patrolling." Flow cytometry showed a similar percentage of classical monocytes in both groups of PCa patient (35.9 ± 5.0% in PCa-M n = 17 and 33.6 ± 4.8% in PCa-N n = 14). Furthermore, when compared to HC blood samples, PCa patients had significantly less inflammatory monocytes ( Figure 1A ). Because CCR2 expression has been described as a marker for inflammatory monocytes and its expression is associated with progression of human breast cancer, 10 we analyzed the expression of CCR2. In all patients analyzed, approximately 95% of the inflammatory monocytes were CCR2 + and there was no difference in CCR2 expression levels between PCa patients and HC individuals ( Figure 1B ). We next examined whether secreted proteins from PCa monocytes or macrophages influenced the metastatic behavior of PCa cells via in vitro invasion assays using LNCaP (castration-sensitive, low metastatic potential) and ARCaP M (castration-resistant, high metastatic potential) cells. We found that LNCaP cells exposed to monocyte-CM from PCa-M became significantly more invasive than when exposed to monocyte-CM from PCa-N (Figure 2A,B) . We also observed that ARCaP M cells tended to be more invasive when exposed to PCa-M monocyte-CM relative to cells exposed to CM from PCa-N ( Figure 2C,D) , though in this sample these differences did not reach statistical significance. Macrophage-CM from PCa-M also increased the invasiveness of PC3 cells ( Figure S1A ) and C4-2 cells ( Figure S1B ). Conversely, macrophage-CM from PCa-N reduced the invasion of these PCa cell lines.
Next, we analyzed whether monocyte-CM from PCa patients affected growth of ARCaP M cells. CM from PCa-M and PCa-N increased the growth of ARCaP M cells similarly to that observed when exposed to media containing 5% FBS ( Figure 2E , absolute numbers and Figure 2F , MTT assay). However, there was no difference in cell growth mediated by monocyte-CM from patients with aggressive or localized disease.
Wound-healing assays were performed using real-time quantitative cell analysis (Incucyte ZOOM System) to determine the effect of monocyte-CM from PCa patients on ARCaP M cell motility. CM-monocytes from PCa-M and PCa-N markedly increased the motility of these cells in a 96-well plates. After overnight fasting, a wound was made in the cell layer and cells were exposed to either 0.1% BSA (fasting media), monocyte-CM from PCa-M (n = 13), PCa-N (n = 16), HC (n = 4), or 5% FBS. All samples were performed in triplicate. Scratched field images were obtained using IncuCyte Live Cell Imaging System, and graphs indicate percentage of relative wound density followed for 72 h from two independent experiments. B, Quantitative analysis of tumor cell motility. Data are mean ± SEM of triplicate wells. PCa-M vs HC #P < 0.05; PCa-N vs HC ##P < 0.01; PCa-M and PCa-N vs FBS **P < 0.001; PCa-M and PCa-N vs fasting media ***P < 0.0001 F I G U R E 4 CHI3L1 and IL-1β are the most abundant proteins secreted by monocytes from metastatic PCa patients. Proteomic profile analysis of monocyte-CM from PCa-M (n = 3), PCa-N (n = 2), and HC (n = 1) collected after 24 h of culture. A-F, Proteins that were up-regulated or down-regulated and reproducible in the patient samples analyzed. **P < 0.01 when PCa-M compared with PCa-N. G, Levels of CHI3L1 analyzed in duplicate. Data are mean ± SEM from each patient or healthy control analyzed in duplicate. ***P < 0.001; ****P < 0.0001 when PCa-M was compared with PCa-N or HC wound-healing assay when compared with CM-monocytes derived from healthy controls (HC), fasting media or 5% FBS. (Figure 3A ,B, Figure S2 ).
| Monocyte-derived conditioned media from metastatic PCa patients contain high levels of IL-1β and CHI3L1
To identify potential proteins secreted by monocytes from PCa-M that might mediate invasiveness of PCa tumor cells, we performed a proteomic profiling analysis of 102 cytokines and chemokines. We compared profiles across CM obtained from PCa-M, PCa-N, and HC. In our analysis, we excluded proteins that were not reproducible among all patients within a category, and any proteins that were coexpressed by PCa and HC. FLT3 ( Figure 4A ), IL-11 ( Figure 4B ), ST2 ( Figure 4C ), IL-13 ( Figure 4D ), IL-1β ( Figure 4E ), and CHI3L1 ( Figure 4F,G) were up-regulated in monocyte-CM from PCa-M but not from PCa-N and HC. Moreover, both CHI3L1 and IL-1β displayed statistically significant up-regulation in PCa-M CM compared with that of PCa-N or HC.
| IL-1β signaling is not responsible for the protumor phenotype of monocytes from PCa-M patients
When stimulated with LPS+ATP (triggering the inflammasome pathway), we observed that monocyte-derived macrophages from PCa-M patients secreted higher levels of IL-1β ( Figure S3A ). These results and our proteomic analysis led us to hypothesize that monocyte-produced IL-1β from PCa-M could be, at least in part, responsible for promoting the invasive behavior of PCa cells. To address this, we analyzed the percentage of FLICA expression as an indicator . Graphs show mean ± SEM of four representative microscope fields per membrane. ***P < 0.001 scrambled siRNA or native vs IL-13Rα2 siRNA of caspase-1 activation after stimulating macrophages with LPS+ATP. Our results showed no significant differences in caspase-1 activation between PCa-N and PCa-M ( Figure  S3B ).
Since it has been shown that IL-1β activates androgenresponsive prostatic epithelial cells, 7 we analyzed the expression of IL-1 receptor type I (IL-1R1) mRNA in several PCa cell lines. We observed a strong expression of IL-1R1 in androgen-responsive 22Rv1, a moderate expression in androgen-independent PC3, and low expression in androgenresistant ARCaP M . Additionally, the presence of recombinant human IL-1β (rhIL1β) did not significantly affect the expression levels of IL-1R1 in any of the three cell lines ( Figure 5A ). The expression of IL-1R2 (decoy receptor) was elevated in PC3 and 22Rv1, but no expression was detected in ARCaP M cells, independent of the presence of rhIL1β ( Figure  S4A ). Furthermore, activation of AR with synthetic androgen (methyltrienolone, R1881) in 22Rv1 cells had no effect on the expression of IL-1R1 ( Figure S4B ), suggesting that IL-1β might affect 22Rv1 independently of AR activation. Next, we directly compared the effects of PCa-M CM vs rhIL1β on PCa cell invasiveness and motility. While PCa-M CM induced invasion in PC3 and ARCaP M cells, the presence of rhIL1β had no effect on invasion ( Figure 5B,C) nor motility ( Figure S5A ,B) at any concentration (0.2, 20, and 100 ng/mL).
Finally, we assessed whether IL1-ILR1 signaling is responsible for invasion of androgen-responsive 22Rv1 cells in the presence of PCa-M monocyte-CM. While monocyte-CM from PCa-M augmented invasion of 22Rv1, the blockage of soluble IL-1β via Anakinra had no effect on tumor cell invasion ( Figure 5D ) or growth ( Figure 5E ). Together, these findings suggest that IL1-IL1R signaling is not the main pathway driving invasiveness of PCa cells.
| CHI3L1 produced by monocyte-CM from metastatic PCa patients modulates the invasion of tumor cells
Recently, it has been shown that CHI3L1 binds interleukin 13 receptor alpha-2 (IL-13Rα2) and that CHI3L1, IL-13Rα2, and IL-13 form a multimeric complex. 11 To explore the role of CHI3L1 in PCa metastatic behavior, we first validated the previous cytokine array data by ELISA ( Figure 6A ). Next, we analyzed the expression of IL-13Rα2 and observed that ARCaP M cells expressed significantly higher transcript levels of IL-13Rα2 compared with PC3, 22Rv1 ( Figure 6B) , and LNCaP cells ( Figure S6A ). Furthermore, IL-13Rα2 transcripts were not detected in monocytes isolated from PCa-M and PCa-N (data not shown). Since it has been previously reported that PCa cell lines secrete CHI3L1, 8 we tested the expression levels in 22Rv1, PC3, and ARCaP M cells. TaqMan analysis showed little to no expression of CHI3L1 in any of the PCa cell lines tested ( Figure 6C ). Next, an siRNA knockdown approach was used to assess whether the CHI3L1/IL-13Rα2 axis might be responsible for PCa tumor cell invasiveness driven by monocyte-CM. IL-13Rα2 knockdown was confirmed by qPCR ( Figure 6D ) and western blot ( Figure 6E ) analysis. Compared to control (scrambled) siRNA, IL-13Rα2 siRNA significantly reduced the ability of PCa-M monocyte-CM to promote invasion of ARCaP M cells ( Figure 6F ). We next tested whether the binding of recombinant human CHI3L1 (rhCHI3L1) to IL-13Rα2 could promote invasion of ARCaP M cells. We found that 10 μM of rhCHI3L1 significantly increased the invasiveness of ARCaP M and this effect was abrogated when IL-13Rα2 was suppressed ( Figure S6B ). IL-13 has been shown to bind with high affinity to IL-13Rα2, thereby promoting invasion and metastasis of ovarian cancer cells. 12 Because we found increased levels of IL-13 in monocyte-CM from PCa-M ( Figure 4D ), we tested the effects of rhIL-13 alone or combined with 10 nmol/L rhCHI3L1 in ARCaP M invasiveness. There was no detectable effect of IL-13 on the invasiveness of ARCaP M cells in the presence or absence of IL-13Rα2 expression (data not shown). Finally, we observed that the transcript expression of IL-13Rα1, the primary receptor for IL-13, in ARCaP M cells was approximately 130-fold lower than IL-13Rα2 transcript levels (data not shown). Together, these findings support a role for monocytederived CHI3L1 in modulating metastasis of PCa. TAMs in the metastatic niches were not analyzed in the present study, we believe that the same described migration of inflammatory monocytes to metastatic sites likely occurs in PCa. Previous studies have shown that the same tumorpromoting functions and gene expression profile in monocytes from renal cell carcinoma (RCC) patients were mirrored in the TAMs isolated from RCC patients and human xenograft tumors. 6 Prior reports addressing the role of myelomonocytic cells in tumor progression have focused mainly on macrophages, while the contributions of circulating blood monocytes in cancer development and progression remain largely unexplored. In the present study, we probed the hypothesis that secreted factors from monocytes alter the invasive properties of PCa cell lines. Specifically, we observed that monocytes from mCRPC promoted tumor invasiveness via an IL-13Rα2-dependent mechanism. These novel findings highlight a new pathway for PCa metastasis and underscore the importance of understanding the contributions of all immune cell types to PCa progression. Human chitinase-like glycoproteins are expressed in several types of solid tumors including breast, colon, kidney, SCLC, ovarian, prostate, and endometrial cancers as well as malignant melanoma, glioblastoma, and Hodgkin's lymphoma. 17, 18 CHI3L1 is a chitinase-like protein lacking enzymatic properties, and its mechanism of action remains an active area of exploration. The CHI3L1 protein was originally discovered in mouse breast cancer cells. 19 More recently, this chitinase-like protein has been directly associated with the progression and aggressiveness of PCa. 20 Although not previously described as a secreted product of monocytes, we discovered that conditioned supernatants from PCa monocytes (and macrophages from the same patients; not shown) contain significant amounts of CHI3L1. Thus, our findings identify, for the first time, that circulating immune cells from advanced metastatic PCa patients secrete higher levels of CHI3L1, leading to increased invasion of tumor cells. Recently, CHI3L1 has been shown to bind the IL-13Rα2 receptor expressed on gastric and breast cancer cells, thereby promoting metastasis of these tumor cells. 21 These investigators showed that the binding of CHI3L1 to IL-13Rα2 results in the recruitment of AP (activator protein)-1 family members, which include several transcription factors important for tumor invasiveness as well as matrix metalloproteases. In our studies, we observed that CHI3L1, but not IL13, mediated IL-13Rα2 activation which promoted tumor invasiveness, suggesting that these two ligands might promote differential signaling through IL-13Rα2. Indeed, similar observations have been made with other cytokine ligand-receptor interactions where it was observed that varying geometries, affinities, and/or duration of contact led to differential signaling. 22, 23 Future studies are warranted to better characterize the signaling pathways activated by CHI3L1 in PCa cells. In summary, we have examined the mechanism by which a protein factor released from activated PCa monocytes contributes to the invasiveness and altered migration of PCa cells in functional in vitro assays. CHI3L1 may be a major factor that mediated these properties in PCa cells, and these effects were dependent on the expression of IL-13Rα2 by PCa cells (Figure 7) . With the continued development of therapeutics targeted toward manipulation of the immune response, altering the secretome from monocytes and macrophages is likely to emerge as an important therapeutic strategy and novel approach in cancer immunotherapy.
| DISCUSSION
